(Q38805517)

6 September 2017

0 references

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis (English)

1 reference

6 September 2017

0 references

0 references

1 reference

1 reference

15

Henrik Zetterberg

1 reference

6 September 2017

14

Kaj Blennow

1 reference

6 September 2017

5

Erik Portelius

1 reference

6 September 2017

6

Maria Bjerke

1 reference

6 September 2017

3

Ulf Andreasson

1 reference

6 September 2017

Bob Olsson

1

1 reference

ORCID Public Data File 2021

author name string

Ronald Lautner

2

1 reference

6 September 2017

Annika Öhrfelt

4

1 reference

6 September 2017

Mikko Hölttä

7

1 reference

6 September 2017

Christoffer Rosén

8

1 reference

6 September 2017

Caroline Olsson

9

1 reference

6 September 2017

Gabrielle Strobel

10

1 reference

6 September 2017

Elizabeth Wu

11

1 reference

6 September 2017

Kelly Dakin

12

1 reference

6 September 2017

Max Petzold

13

1 reference

6 September 2017

8 April 2016

1 reference

6 September 2017

1 reference

6 September 2017

15

1 reference

6 September 2017

7

1 reference

6 September 2017

673-684

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900070-3

6 September 2017

1 reference

7 January 2021

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900070-3

7 January 2021

CSF tau markers are correlated with hippocampal volume in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900070-3

7 January 2021

Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900070-3

7 January 2021

Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900070-3

7 January 2021

Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900070-3

7 January 2021

CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900070-3

7 January 2021

CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900070-3

7 January 2021

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900070-3

7 January 2021

New criteria for Alzheimer's disease: which, when and why?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900070-3

7 January 2021

Progress update: fluid and imaging biomarkers in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900070-3

7 January 2021

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900070-3

7 January 2021

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900070-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900070-3

7 January 2021

Brain Enolases as Specific Markers of Neuronal and Glial Cells

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900070-3

7 January 2021

Identification of novel brain biomarkers.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900070-3

7 January 2021

A Binding Protein for Fatty Acids in Cytosol of Intestinal Mucosa, Liver, Myocardium, and Other Tissues

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900070-3

7 January 2021

YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates the biological activity of basic fibroblast growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900070-3

7 January 2021

Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900070-3

7 January 2021

Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900070-3

7 January 2021

Biomarker-based dissection of neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900070-3

7 January 2021

Development and validation of methods for assessing the quality of diagnostic accuracy studies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900070-3

7 January 2021

The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900070-3

7 January 2021

Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900070-3

7 January 2021

CSF biomarker variability in the Alzheimer's Association quality control program

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900070-3

7 January 2021

The ratio of means method as an alternative to mean differences for analyzing continuous outcome variables in meta-analysis: a simulation study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900070-3

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900070-3

7 January 2021

Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900070-3

7 January 2021

Soluble amyloid-β levels and late-life depression

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900070-3

7 January 2021

Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900070-3

7 January 2021

Clinical and biomarker changes in dominantly inherited Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900070-3

7 January 2021

Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900070-3

7 January 2021

10.1016/S1474-4422(16)00070-3

Identifiers

DOI

1 reference

release_l6cxjo7y6fgphnd6lqtyftyu5u

6 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/l6cxjo7y6fgphnd6lqtyftyu5u

24 November 2022

mapped directly with Wikidata item

1 reference